Evidence map›Paper›PMID 35615323›Full record

ArticleMediterranean journal of hematology and infectious diseases2022

The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.

Antonio Cristiano, Raffaele Palmieri, Emiliano Fabiani, Tiziana Ottone, Mariadomenica Divona, Arianna Savi, Francesco Buccisano, Luca Maurillo, Corrado Tarella, William Arcese and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Antonio CristianoDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Raffaele PalmieriDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Emiliano FabianiDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Tiziana OttoneDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Mariadomenica DivonaDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Arianna SaviDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Francesco BuccisanoDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Luca MaurilloDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Corrado TarellaEuropean Institute of Oncology (IEO) and University of Milan, Milan, Italy.
William ArceseDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," Rome, Italy.
University of Rome Tor Vergata · ITEuropean Institute of Oncology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The addition of Venetoclax (VEN) to Hypomethylating agents (HMAs) significantly improves the probability of complete remission and prolongs survival in patients with Acute Myeloid Leukemia (AML) when compared to HMA alone. However, the mutated clone composition may impact the probability of response and its duration. Here, we describe the molecular profile of a patient with AML rapidly evolved from a previous therapy-related-Chronic MyeloMonocytic Leukemia, who achieved safely complete remission after treatment with the VEN/Azacitidine combination, even in the presence of SARS-COVID-2 infection. The targeted NGS analysis showed that the VEN/AZA combination led to the eradication of the

Indexed as

AMLtargeted-NGSt-CMMLVenetoclaxVenetoclax/azacitidine combination

Identifiers

PMID35615323
PMCPMC9083951
OpenAlexW4285740687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.